Skip to main content

Table 2 Patient characteristics during ICU stay

From: Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study

 

No corticosteroids (n = 354)

Corticosteroids (n = 191)

Corticosteroids

 Hydrocortisone

–

52/187 (27.8)

 Dexamethasone

–

46/187 (24.6)

 Methylprednisolone

–

90/187 (48.1)

 Highest daily dose, mg

–

100 (50–133)

 Exposure period, days

–

6 (3–8)

Antibiotic treatment

308/328 (93.9)

177/182 (97.3)

 Duration, days

12 (7–18)

14 (9–20)

Prone positioning

228/353 (64.6)

143/191 (74.9)

ECMO

39/354 (11.0)

22/190 (11.6)

28-day outcomes

 MV duration, days

14 (8–22)

17 (10–25)

 28-day mortality

93/354 (26.3)

70/191 (36.6)

 ICU length of stay, days

17 (11–27)

20 (13–28)

  1. Values are as no./No.(%) or median (interquartile range)
  2. Highest daily dose of corticosteroids is reported as prednisone equivalent. Exposure period is defined from the day of initiation of corticosteroids until the occurrence of VAP or MV withdrawal or death within the 28-day of follow-up
  3. ECMO extracorporeal membrane oxygenation, ICU intensive care unit, MV mechanical ventilation
Back to article page

Critical Care

ISSN: 1364-8535